Theravance Biopharma (NASDAQ: TBPH) reported Q1 EPS of ($1.10), $0.14 worse than the analyst estimate of ($0.96). Revenue for the quarter came in at $18.4 million versus the consensus estimate of $18.69 million.

For earnings history and earnings-related data on Theravance Biopharma (TBPH) click here.